SOUTH SAN FRANCISCO, Calif., March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief ...
Rigel Pharma has 2 FDA-approved drugs: Tavalisse for chronic immune thrombocytopenia (ITP) and Rezlidhia for relapsed or refractory AML with susceptible IDH1 mutation. In Q4 2022, Tavalisse revenue ...
SOUTH SAN FRANCISCO, Calif., July 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved ...
Rigel Pharmaceuticals reported promising preliminary Q4 and full-year 2023 results, with record-breaking net product sales for TAVALISSE and REZLIDHIA. The company's cash position remains healthy, ...
Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $1.46 per share, beating the Zacks Consensus Estimate of $0.93 per share. This compares to earnings of $0.7 per share a year ago. These ...
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that REZLIDHIA™ (olutasidenib) capsules are available in the U.S. by prescription ...
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Kamil Ali-Jackson to the company's Board of Directors. Ms.
Rigel's new rheumatoid arthritis pill might change the way medical professionals treat autoimmune diseases from now on. Rigel Pharmaceuticals skyrocketed after the company announced that its latest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback